Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinge Zhao

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
BJU International|May 18, 2018
Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancerJinge Zhao, Guangxi Sun, Banghua Liao, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and AdolescentsHaoyang Liu, Haolin Liu, Junru Chen, et al.
Molecular Cancer|June 26, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinomaJunjie Zhao, Yanfeng Tang, Xu Hu, et al.
BMC Medicine|July 21, 2022
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)Sha Zhu, Jinge Zhao, Ling Nie, et al.
Quantitative Imaging in Medicine and Surgery|July 29, 2025
Predicting pathogenic DNA damage repair gene mutations in prostate cancer patients: a multi-center magnetic resonance imaging radiomics studyYuntian Chen, Jinge Zhao, Lei Ye, et al.
Journal of Multidisciplinary Healthcare|March 3, 2023
Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma PatientsYuhao Zeng, Sha Zhu, Zilin Wang, et al.
BJU International|June 29, 2021
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostateJinge Zhao, Guangxi Sun, Sha Zhu, et al.
Journal for Immunotherapy of Cancer|May 28, 2026
Pretreatment intratumoral mature TLSs in non-clear cell renal cell carcinoma are associated with response to immunotherapy rechallengeYanfeng Tang, Junru Chen, Jue Hu, et al.
Journal of Cancer Research and Clinical Oncology|March 13, 2023
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancerNanwei Xu, Jinge Zhao, Fengnian Zhao, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
BJU International|May 18, 2018
Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancerJinge Zhao, Guangxi Sun, Banghua Liao, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and AdolescentsHaoyang Liu, Haolin Liu, Junru Chen, et al.
Molecular Cancer|June 26, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinomaJunjie Zhao, Yanfeng Tang, Xu Hu, et al.
BMC Medicine|July 21, 2022
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)Sha Zhu, Jinge Zhao, Ling Nie, et al.
Quantitative Imaging in Medicine and Surgery|July 29, 2025
Predicting pathogenic DNA damage repair gene mutations in prostate cancer patients: a multi-center magnetic resonance imaging radiomics studyYuntian Chen, Jinge Zhao, Lei Ye, et al.
Journal of Multidisciplinary Healthcare|March 3, 2023
Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma PatientsYuhao Zeng, Sha Zhu, Zilin Wang, et al.
BJU International|June 29, 2021
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostateJinge Zhao, Guangxi Sun, Sha Zhu, et al.
Journal for Immunotherapy of Cancer|May 28, 2026
Pretreatment intratumoral mature TLSs in non-clear cell renal cell carcinoma are associated with response to immunotherapy rechallengeYanfeng Tang, Junru Chen, Jue Hu, et al.
Journal of Cancer Research and Clinical Oncology|March 13, 2023
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancerNanwei Xu, Jinge Zhao, Fengnian Zhao, et al.
Pageof 10